Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. more
Time Frame | TSHA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.96% | -0.94% | -2.6% |
1-Month Return | -36.68% | -5.08% | -1.08% |
3-Month Return | -9.85% | -10.62% | 3.45% |
6-Month Return | -31.2% | -6.18% | 8.57% |
1-Year Return | 8.28% | 1.98% | 24.3% |
3-Year Return | -85.65% | -0.93% | 25.58% |
5-Year Return | -92.39% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 2.50M | 15.45M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":16.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | - | 9.00K | 492.00K | 2.49M | 1.37M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.36,"profit":true},{"date":"2021-12-31","value":19.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":55.13,"profit":true}] |
Gross Profit | - | (9.00K) | (492.00K) | 15.00K | 15.45M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.06,"profit":false},{"date":"2021-12-31","value":-3.18,"profit":false},{"date":"2022-12-31","value":0.1,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | (Infinity%) | (Infinity%) | 0.60% | 100.00% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":0.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 1.11M | 43.00M | 173.27M | 128.53M | 87.89M | [{"date":"2019-12-31","value":0.64,"profit":true},{"date":"2020-12-31","value":24.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.18,"profit":true},{"date":"2023-12-31","value":50.73,"profit":true}] |
Operating Income | (1.11M) | (43.00M) | (173.27M) | (162.45M) | (72.44M) | [{"date":"2019-12-31","value":-111500000,"profit":false},{"date":"2020-12-31","value":-4300200000,"profit":false},{"date":"2021-12-31","value":-17326700000,"profit":false},{"date":"2022-12-31","value":-16244700000,"profit":false},{"date":"2023-12-31","value":-7243900000,"profit":false}] |
Total Non-Operating Income/Expense | - | (16.99M) | (2.51M) | (7.12M) | (42.87M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1698800000,"profit":false},{"date":"2021-12-31","value":-251200000,"profit":false},{"date":"2022-12-31","value":-711600000,"profit":false},{"date":"2023-12-31","value":-4286700000,"profit":false}] |
Pre-Tax Income | (1.11M) | (60.01M) | (174.52M) | (166.01M) | (111.57M) | [{"date":"2019-12-31","value":-111500000,"profit":false},{"date":"2020-12-31","value":-6001100000,"profit":false},{"date":"2021-12-31","value":-17452300000,"profit":false},{"date":"2022-12-31","value":-16601400000,"profit":false},{"date":"2023-12-31","value":-11156600000,"profit":false}] |
Income Taxes | (4.46M) | (17.01M) | 936.00K | 3.57M | 1.20M | [{"date":"2019-12-31","value":-125.04,"profit":false},{"date":"2020-12-31","value":-476.9,"profit":false},{"date":"2021-12-31","value":26.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":33.73,"profit":true}] |
Income After Taxes | - | (43.00M) | (175.46M) | (169.58M) | (112.77M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-4300000000,"profit":false},{"date":"2021-12-31","value":-17545900000,"profit":false},{"date":"2022-12-31","value":-16958100000,"profit":false},{"date":"2023-12-31","value":-11276910500,"profit":false}] |
Income From Continuous Operations | - | (60.01M) | (174.52M) | (166.01M) | (214.38M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-6001100000,"profit":false},{"date":"2021-12-31","value":-17452300000,"profit":false},{"date":"2022-12-31","value":-16601400000,"profit":false},{"date":"2023-12-31","value":-21438500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (1.11M) | (43.00M) | (175.46M) | (169.58M) | (111.57M) | [{"date":"2019-12-31","value":-111500000,"profit":false},{"date":"2020-12-31","value":-4300000000,"profit":false},{"date":"2021-12-31","value":-17545900000,"profit":false},{"date":"2022-12-31","value":-16958100000,"profit":false},{"date":"2023-12-31","value":-11156600000,"profit":false}] |
EPS (Diluted) | - | (3.60) | (4.63) | (3.78) | 0.13 | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2769.23,"profit":false},{"date":"2021-12-31","value":-3561.54,"profit":false},{"date":"2022-12-31","value":-2907.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
TSHA | |
---|---|
Cash Ratio | 5.38 |
Current Ratio | 5.51 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TSHA | |
---|---|
ROA (LTM) | -27.42% |
ROE (LTM) | -114.77% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TSHA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.51 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.49 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TSHA | |
---|---|
Trailing PE | 2.94 |
Forward PE | NM |
P/S (TTM) | 38.24 |
P/B | 4.27 |
Price/FCF | NM |
EV/R | 28.64 |
EV/Ebitda | NM |
Taysha Gene Therapies Inc (TSHA) share price today is $1.83
Yes, Indians can buy shares of Taysha Gene Therapies Inc (TSHA) on Vested. To buy Taysha Gene Therapies Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TSHA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Taysha Gene Therapies Inc (TSHA) via the Vested app. You can start investing in Taysha Gene Therapies Inc (TSHA) with a minimum investment of $1.
You can invest in shares of Taysha Gene Therapies Inc (TSHA) via Vested in three simple steps:
The 52-week high price of Taysha Gene Therapies Inc (TSHA) is $4.32. The 52-week low price of Taysha Gene Therapies Inc (TSHA) is $1.19.
The price-to-earnings (P/E) ratio of Taysha Gene Therapies Inc (TSHA) is 2.9365
The price-to-book (P/B) ratio of Taysha Gene Therapies Inc (TSHA) is 4.27
The dividend yield of Taysha Gene Therapies Inc (TSHA) is 0.00%
The market capitalization of Taysha Gene Therapies Inc (TSHA) is $379.14M
The stock symbol (or ticker) of Taysha Gene Therapies Inc is TSHA